Lysogene concludes patient recruitment in SAMOS trial for MPS IIIA

French biopharmaceutical firm Lysogene has completed patient enrolment for its Sanfilippo A multi-national observational study (SAMOS) to treat mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo A.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Study